The Senate has passed a bill requiring the FDA to provide educational information that supports and promotes the adoption of biosimilars.
The US Senate has passed a bill that would require the FDA to beef up education on biosimilars in order to improve uptake of these lower-cost agents, which are considered as safe and efficacious as the originator biologics they are patterned after.
The Advancing Education on Biosimilars Act was approved unanimously. The bill (S 1681) was co-sponsored by Senator Maggie Hassan, D-New Hampshire. “Our bipartisan legislation will help lower the cost of health care by educating more Granite Staters and Americans about biosimilars—an under-the-radar alternative to expensive brand-name drugs,” Hassan said in a statement.
The Senate version of the bill was introduced in May 2019 and was voted on successfully in December 2020 but required a fresh vote this year.
Under the bill, the FDA would be required to create a biosimilars education website with information on biosimilars and other biologics covering key statutory and regulatory terms used to describe and classify biosimilars, such as interchangeability. It would have to be tailored to the unique needs of health care providers, meaning the material should be appropriately presented and explained.
The bill would also require that comparative data for originator biologics and biosimilars is made available; and, on an ongoing basis, continuing education programs would have to be maintained to inform health care providers, including nurses, about biosimilars.
A House version of the bill (HR 4400) was introduced in September 2019 and referred to the Subcommittee on Health.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.